Abstract
Patient preferences have become an important focus for inclusion in drug development and evaluation. Understanding patient preferences is especially valuable in Multiple Myeloma (MM), where the rapid development of treatments with diverging benefit-risk profiles raises uncertainty about what matters most to patients. This study aimed to investigate which treatment attributes (side-effects, symptoms, efficacy outcomes, uncertainties) are most important to MM patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
